Sep. 6, 2012 Intermittent Hormone Therapy Be Effective For Certain Prostate Cancer Patients
Posted on September 6, 2012
Dr. Whang comments
Many urologists have treated their patients with metastatic prostate cancer with intermittent hormonal therapy. Recently at the ASCO (American Society of Clinical Oncologists) meeting, a paper was presented that intermittent hormonal therapy was inferior to continuous hormonal therapy.
Here is a study that says the opposite.
Bottomline: we don’t have definite answers in this situation yet.
More important issue is to diagnose prostate cancer early and treat it to cure it so that it doesn’t get to the metastatic point. When patient does develop metastatic cancer, we now have more weapons than in the past and we can provide better quality of life as well as longevity.
Intermittent Hormone Therapy Be Effective For Certain Prostate Cancer Patients.
WebMD (9/6, Boyles) reports, “‘Start and stop’ hormone therapy is as effective as continuous therapy in the treatment of some prostate cancer patients,” according to a study published in the New England Journal of Medicine.
HealthDay (9/6, Salamon) reports, “For the study…nearly 1,400 patients whose localized prostate cancer was treated with surgery and/or radiation were split into two groups.” One group “received continuous hormone-deprivation therapy – a mainstay treatment for prostate cancer that has spread – while the rest were treated in eight-month cycles punctuated by months-long ‘breaks’ depending on their PSA levels.”
MedPage Today (9/6, Bankhead) reports, “Median overall survival was 8.8 years with intermittent therapy and 9.1 years with continuous therapy, and the seven-year estimated disease-related mortality was 18% and 15%, respectively. Neither difference was statistically significant.” Investigators reported that “men who received intermittent therapy appeared to benefit on several functional, symptomatic, and sexual outcomes.”
Medscape (9/6, Chustecka) reports, “One of the study authors suggested that intermittent ADT should become a standard of care in this patient population, as it reduces side effects without reducing survival.”
Posted in Uncategorized